logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Short Report

Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs

Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y,  et al.
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of ...
Journal Article
|
Protocol

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Journal Article
|
Research

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort

Hewison CCH, Khan UT, Bastard M, Lachenal N, Coutisson S,  et al.
2022-09-15 • Clinical Infectious Diseases
2022-09-15 • Clinical Infectious Diseases
RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.

OBJECTIVES
Evaluate safety of longer MDR/RR-TB...
Journal Article
|
Research

Setting up pharmacovigilance based on available endTB project data for bedaquiline

Lachenal N, Hewison CCH, Mitnick CD, Lomtadze N, Coutisson S,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support of UNIT...
Journal Article
|
Research

One step forward: successful end-of-treatment outcomes of patients with drug-resistant tuberculosis who received concomitant bedaquiline and delamanid in Mumbai, India

Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F,  et al.
2021-11-02 • Clinical Infectious Diseases
2021-11-02 • Clinical Infectious Diseases
BACKGROUND
The Médecins Sans Frontières clinic in Mumbai, India, has been providing concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with drug-resi...
Technical Report
|
Study report

endTB interim analysis report - Bedaquiline- and delaminid- containing regimens achieve excellent interim treatment response without safety concerns

Atwood S, Avagyan N, Bastard M, Cain M, Collin S,  et al.
2018-07-01
2018-07-01
Journal Article
|
Research

One step forward: Successful end-of-treatment outcomes of drug-resistant TB patients who received concomitant bedaquiline and delamanid in Mumbai, India

Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F,  et al.
2020-10-20 • Clinical Infectious Diseases
2020-10-20 • Clinical Infectious Diseases
Background
Médecins Sans Frontières clinic in Mumbai, India has been providing concomitant Bedaquiline (BDQ) and Delamanid (DLM) in treatment regimen for patients with drug-resistan...